Kiniksa Pharmaceuticals International, plc (KNSA)
NASDAQ · Healthcare
Kiniksa Pharmaceuticals International, plc Operating Income 2021–2025
Kiniksa Pharmaceuticals International, plc annual/quarterly operating income history and growth rate from 2021 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Kiniksa Pharmaceuticals International, plc operating income for the quarter ending March 31, 2026 was 29.3 M, a 120.52% increase year-over-year.
- Kiniksa Pharmaceuticals International, plc operating income for the twelve months ending March 31, 2026 was 86.7 M, a 332.84% decrease year-over-year.
- Kiniksa Pharmaceuticals International, plc annual operating income for 2025 was 77.2 M, a 269.28% decrease from 2024.
- Kiniksa Pharmaceuticals International, plc annual operating income for 2024 was -45.6 M, a 81.04% increase from 2023.
- Kiniksa Pharmaceuticals International, plc annual operating income for 2023 was -25.2 M, a 357.81% decrease from 2022.
- Kiniksa Pharmaceuticals International, plc annual operating income for 2022 was 9.8 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Kiniksa Pharmaceuticals International, plc Operating Income — FAQ
Kiniksa Pharmaceuticals International, plc (KNSA) operating income over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is Kiniksa Pharmaceuticals International, plc's operating income?
Kiniksa Pharmaceuticals International, plc (KNSA) reported operating income of $77M for fiscal 2025.
Where can I see KNSA's operating income history?
The chart and table above show Kiniksa Pharmaceuticals International, plc's operating income by year and by quarter, including the growth rate.